BRCA1/2 携带者 RRSO 后子宫内膜癌风险：一项多中心队列研究。
Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study.
机构信息
Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Avinguda de França s/n, 17707, Girona, Spain.
Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
出版信息
Clin Transl Oncol. 2024 Apr;26(4):1033-1037. doi: 10.1007/s12094-023-03312-4. Epub 2023 Sep 8.
OBJECTIVE
To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO).
METHODS
The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry.
RESULTS
After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93-3.95).
CONCLUSIONS
In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients.
目的
了解进行 BRCA1/2 致病性或可能致病性变异风险降低的输卵管卵巢切除术（RRSO）后，BRCA1/2 致病性或可能致病性变异患者人群中子宫内膜癌（EC）的风险。
方法
该研究队列纳入了自 1999 年 1 月 1 日至 2019 年 4 月 30 日在西班牙加泰罗尼亚的四家医院接受 RRSO 的 857 名 BRCA 突变女性的数据。使用区域性基于人群的癌症登记处的数据，计算这些患者中 EC 的标准化发病比（SIR）。
结果
RRSO 后，共发现 8 例 EC 病例。BRCA1 携带者中有 4 例，BRCA2 携带者中有 4 例。EC 的预期病例数为 3.67 例，SIR 为 2.18，95%CI（0.93-3.95）。
结论
在我们的队列中，RRSO 后 BRCA1/2 携带者中 EC 的风险并不高于预期。不常规建议对这些患者进行子宫切除术。
Zotero 插件